The Eighth Annual International Employment Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Eighth Annual International Employment Survey


Pharmaceutical Technology



Figure 6: A steady, and almost predictable, increase in annual compensation continues to contribute to overall employment stability and security.
These initiatives are not the only government decisions affecting pharma workers. "The biggest change in how we do business is [the] Sarbanes-Oxley [Act]," says Allen Bokser, director of analytical R&D at Hollis-Eden Pharmaceuticals (San Diego, CA, http://www.hollisedin.com/), a virtual biotech company that relies entirely on contract testing and manufacturing services. In many cases, that legislation has resulted in extra documentation and extra time needed to complete routine tasks such as obtaining contracts and making purchase orders, especially when conducting business with international service providers.

Summary

The pharmaceutical industry continues to provide a stable job market. Overall, US respondents have continued to see a steady increase in their annual salaries (see Figure 6), including a 5% increase over 2004. Women in aggregate continue to earn about 20% less than their male colleagues. Although there is a 6% increase in those who foresee a job change within the next 12 months, nearly 70% of all employees agree or strongly agree their jobs are secure.

Reference

1. US Department of Labor and the US Bureau of Labor Statistics "Highlights of Women's Earnings in 2004," report 987, Sept. 2005, http://stats.bls.gov/.

Photos courtesy of Sartorius Corporation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here